[go: up one dir, main page]

CR9263A - USO DE AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO PARA LA MUCOSITIS INDUCIDA POR RADIACION O POR QUIMIOTERAPIA Y PARA LA CISTITIS INDUCIDA POR RADIACION - Google Patents

USO DE AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO PARA LA MUCOSITIS INDUCIDA POR RADIACION O POR QUIMIOTERAPIA Y PARA LA CISTITIS INDUCIDA POR RADIACION

Info

Publication number
CR9263A
CR9263A CR9263A CR9263A CR9263A CR 9263 A CR9263 A CR 9263A CR 9263 A CR9263 A CR 9263A CR 9263 A CR9263 A CR 9263A CR 9263 A CR9263 A CR 9263A
Authority
CR
Costa Rica
Prior art keywords
radiation
mucositis
strogen
chemotherapy
receiver
Prior art date
Application number
CR9263A
Other languages
English (en)
Inventor
Jacobson William
A Harris Heather
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36597596&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR9263A publication Critical patent/CR9263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invencion provee un metodo para tratar o inhibir la mucositis o la cistitis por radiacion, utilizando un ligando selectivo para ERB no uterotrofico, no mamotrofico. La presente invencion tambien provee composiciones, incluyendo composiciones farmaceuticas, que contienen el ligando selectivo para ERB no uterotrofico, no mamotrofico y un medicamento tradicional para la mucositis o cistitis por radiacion.
CR9263A 2005-02-16 2007-07-20 USO DE AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO PARA LA MUCOSITIS INDUCIDA POR RADIACION O POR QUIMIOTERAPIA Y PARA LA CISTITIS INDUCIDA POR RADIACION CR9263A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65337605P 2005-02-16 2005-02-16

Publications (1)

Publication Number Publication Date
CR9263A true CR9263A (es) 2007-11-23

Family

ID=36597596

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9263A CR9263A (es) 2005-02-16 2007-07-20 USO DE AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO PARA LA MUCOSITIS INDUCIDA POR RADIACION O POR QUIMIOTERAPIA Y PARA LA CISTITIS INDUCIDA POR RADIACION

Country Status (20)

Country Link
US (1) US20060211672A1 (es)
EP (1) EP1848427A1 (es)
JP (1) JP2008530210A (es)
KR (1) KR20070103456A (es)
CN (1) CN101119721A (es)
AR (1) AR053332A1 (es)
AU (1) AU2006214515A1 (es)
BR (1) BRPI0608154A2 (es)
CA (1) CA2596984A1 (es)
CR (1) CR9263A (es)
GT (1) GT200600064A (es)
IL (1) IL185009A0 (es)
MX (1) MX2007009914A (es)
NI (1) NI200700182A (es)
NO (1) NO20073901L (es)
PE (1) PE20061092A1 (es)
RU (1) RU2007128819A (es)
TW (1) TW200640451A (es)
WO (1) WO2006088784A1 (es)
ZA (1) ZA200706785B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0707655A2 (pt) * 2006-02-14 2011-05-10 Wyeth Corp composiÇço farmacÊutica aquosa, mÉtodo para preparar uma composiÇço farmacÊutica, produto, mÉtodo para tratar um indivÍduo sofrendo de artrite ou endometriose, e, kit
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
KR101763674B1 (ko) 2007-01-22 2017-08-01 지티엑스, 인코포레이티드 핵 수용체에 결합하는 물질
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US20150018398A1 (en) * 2013-07-15 2015-01-15 The Regents Of The University Of California Methods of using estrogen receptor-beta ligands as radiation mitigators
EP3906508B1 (en) * 2018-12-31 2024-03-13 Intel Corporation Securing systems employing artificial intelligence

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496828A (en) * 1994-08-22 1996-03-05 Eli Lilly And Company Methods of inhibiting ulcerative mucositis
JP2000506529A (ja) * 1996-03-11 2000-05-30 イーライ・リリー・アンド・カンパニー 間質性膀胱炎の処置または予防方法
SK9592002A3 (en) * 2000-01-28 2003-12-02 Endorech Inc A method for reduction or elimination of the incidence of menopausal symptoms, method of treatment or decreasing the risk of an acquiring disease, a pharmaceutical composition and a kit
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
PT1997478E (pt) * 2001-02-15 2013-12-10 Access Pharma Inc Formulações líquidas para a prevenção e para o tratamento de doenças e distúrbios das mucosas
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6914074B2 (en) * 2001-12-13 2005-07-05 Wyeth Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US20030220377A1 (en) * 2002-05-08 2003-11-27 Richard Chesworth Indole compounds and their use as estrogen agonists/antagonists
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc

Also Published As

Publication number Publication date
NO20073901L (no) 2007-11-15
AR053332A1 (es) 2007-05-02
NI200700182A (es) 2008-05-13
CN101119721A (zh) 2008-02-06
WO2006088784A1 (en) 2006-08-24
EP1848427A1 (en) 2007-10-31
IL185009A0 (en) 2008-08-07
US20060211672A1 (en) 2006-09-21
AU2006214515A1 (en) 2006-08-24
TW200640451A (en) 2006-12-01
BRPI0608154A2 (pt) 2016-10-11
MX2007009914A (es) 2007-09-25
KR20070103456A (ko) 2007-10-23
GT200600064A (es) 2006-11-09
JP2008530210A (ja) 2008-08-07
ZA200706785B (en) 2009-08-26
RU2007128819A (ru) 2009-03-27
CA2596984A1 (en) 2006-08-24
PE20061092A1 (es) 2006-12-05

Similar Documents

Publication Publication Date Title
CL2007000311A1 (es) Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2008001656A1 (es) Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene.
CR10433A (es) Compuestos organicos y sus usos
CR10310A (es) Compuestos nuevos
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
CL2007003797A1 (es) Compuestos derivados de pirrolo piridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la enfermedad de alzheimer, parkinson, cancer, entre otras enfermedades.
CL2008001682A1 (es) Metodos para el mejoramiento de plantas mediante el uso de informacion directa de secuencias de acidos nucleicos.
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CL2007003244A1 (es) Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
BRPI0517238A (pt) formulações que compreendem ecteinascidina e um dissacarìdeo
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2007002856A1 (es) Compuestos derivados de pirazolo(1,5)pirimidina; composicion farmaceutica qu lo comprende;y su uso para tratar el cancer.
CL2007003138A1 (es) Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007002100A1 (es) Compuestos derivados biciclicos que contienen nitrogeno, sus sales, solvatos y n-oxidos; composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
ECSP088676A (es) Pirazolquinolonas como potentes inhibidores de parp
CL2008001057A1 (es) Agente para el tratamiento de micosis producida por saprolegnia, achlya y/o aphanomyces en peces, el cual comprende al menos un fungicida seleccionado entre a) inhibidores de l a mitosis y division celular, b) inhiidores de la sintesis de ergosterol o, c) derivados de piridina, benzopiranona, carbonitrilo,quinolinas, entre otras.
AR064955A1 (es) Composicion y metodo para estabilizar ingredientes sensibles
DOP2010000062A (es) Derivados de ciclopropilamida
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
CR9263A (es) USO DE AGONISTAS SELECTIVOS PARA EL RECEPTOR-ß DE ESTROGENO PARA LA MUCOSITIS INDUCIDA POR RADIACION O POR QUIMIOTERAPIA Y PARA LA CISTITIS INDUCIDA POR RADIACION
DOP2006000268A (es) Agentes antibacterianos
CL2020003306A1 (es) Composiciones bifuncionales para el tratamiento del cáncer.
PA8667201A1 (es) Nuevos compuestos farmaceuticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)